The earnings call presented a mixed picture. While there were significant advancements in international expansion, FDA treatment volume, and potential reimbursement improvements, these were overshadowed by declines in revenue, gross profit, and increased operating expenses. The proposed LCD has also created uncertainty, affecting domestic sales momentum.

Company Guidance -

Q3 2025

During the second quarter of 2025, Sensus Healthcare faced several challenges that impacted their financial results and guidance. Revenue declined to $7.3 million from $9.2 million in the same period of 2024, primarily due to fewer capital system sales, which were affected by a proposed local coverage determination (LCD) that questioned the frequency of ultrasound use with the SRT-100 Vision systems. Gross profit dropped to $2.9 million with a 39.7% margin compared to a 58.7% margin in the prior year. Operating expenses increased across the board, with general and administrative costs rising to $2 million, selling and marketing costs to $1.4 million, and research and development expenses to $1.5 million, contributing to a net loss of $1 million compared to a net income of $1.6 million last year. Despite these setbacks, Sensus made notable progress in international markets, delivering 19 SRT systems, including four to China, and achieving MDSAP certification, which opens access to new markets. They also expanded their U.S. commercial footprint through a new partnership with Radiation Oncology Systems. While the company is optimistic about its long-term prospects, including potential benefits from a proposed increase in the Medicare physician fee schedule for SRT delivery, the immediate outlook remains contingent on resolving ongoing reimbursement uncertainties.

FDA Treatment Volume Increase

FDA treatment volume increased by 27% over Q1, indicating more efficient practices and increased patient awareness of SRT as a preferred treatment option.

International Expansion

Sensus delivered 19 SRT systems, including 4 to China, indicating growing international demand. The company achieved MDSAP certification, providing access to Brazil, Canada, Japan, and Australia markets.

New Distribution Partnership

Sensus expanded its U.S. footprint by appointing Radiation Oncology Systems as the primary distribution partner for the hospital-based oncology segment.

Potential Medicare Reimbursement Increase

Medicare proposed a physician fee schedule that could significantly increase reimbursement for SRT delivery codes.

Sensus Healthcare (SRTS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRTS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.04 / -	0.07	―	―	―
Aug 07, 2025	2025 (Q2)	0.03 / -0.06	0.1	-160.00% (-0.16)	―
May 15, 2025	2025 (Q1)	0.03 / -0.16	0.14	-214.29% (-0.30)	―
Feb 05, 2025	2024 (Q4)	0.12 / 0.09	0.26	-65.38% (-0.17)	―
Nov 14, 2024	2024 (Q3)	-0.01 / 0.07	-0.09	177.78% (+0.16)	―
Aug 08, 2024	2024 (Q2)	0.02 / 0.10	-0.02	600.00% (+0.12)	―
May 09, 2024	2024 (Q1)	-0.04 / 0.14	-0.12	216.67% (+0.26)	―
Feb 08, 2024	2023 (Q4)	0.14 / 0.26	0.17	52.94% (+0.09)	―
Nov 09, 2023	2023 (Q3)	-0.02 / -0.09	0.11	-181.82% (-0.20)	―
Aug 03, 2023	2023 (Q2)	-0.08 / -0.02	0.21	-109.52% (-0.23)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SRTS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.35	$3.46	-35.33%
May 15, 2025	$4.66	$4.46	-4.29%
Feb 05, 2025	$8.99	$6.08	-32.37%
Nov 14, 2024	$7.29	$7.64	+4.80%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sensus Healthcare, Inc. (SRTS) report earnings?

Sensus Healthcare, Inc. (SRTS) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Sensus Healthcare, Inc. (SRTS) earnings time?

Sensus Healthcare, Inc. (SRTS) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SRTS EPS forecast?

SRTS EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing